CN103249407B - 用于治疗抑郁症和其他非感染性疾病的联合疗法 - Google Patents

用于治疗抑郁症和其他非感染性疾病的联合疗法 Download PDF

Info

Publication number
CN103249407B
CN103249407B CN201180058704.9A CN201180058704A CN103249407B CN 103249407 B CN103249407 B CN 103249407B CN 201180058704 A CN201180058704 A CN 201180058704A CN 103249407 B CN103249407 B CN 103249407B
Authority
CN
China
Prior art keywords
glucosamine
treatment
vitamin
glycine
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180058704.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN103249407A (zh
Inventor
P·特纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EaglePharma Pty Ltd
Original Assignee
EaglePharma Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2010904479A external-priority patent/AU2010904479A0/en
Application filed by EaglePharma Pty Ltd filed Critical EaglePharma Pty Ltd
Publication of CN103249407A publication Critical patent/CN103249407A/zh
Application granted granted Critical
Publication of CN103249407B publication Critical patent/CN103249407B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201180058704.9A 2010-10-07 2011-10-05 用于治疗抑郁症和其他非感染性疾病的联合疗法 Active CN103249407B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2010904479 2010-10-07
AU2010904479A AU2010904479A0 (en) 2010-10-07 The use of a novel compound GMGB1 in the treatment of depression and other non-infectious diseases
PCT/AU2011/001275 WO2012045118A1 (fr) 2010-10-07 2011-10-05 Polythérapie destinée au traitement de la dépression et d'autres maladies non infectieuses

Publications (2)

Publication Number Publication Date
CN103249407A CN103249407A (zh) 2013-08-14
CN103249407B true CN103249407B (zh) 2017-05-17

Family

ID=45927130

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180058704.9A Active CN103249407B (zh) 2010-10-07 2011-10-05 用于治疗抑郁症和其他非感染性疾病的联合疗法

Country Status (6)

Country Link
US (2) US20130281401A1 (fr)
EP (1) EP2624821B1 (fr)
CN (1) CN103249407B (fr)
AU (1) AU2011313814B2 (fr)
CA (1) CA2816595C (fr)
WO (1) WO2012045118A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9387218B2 (en) 2012-04-02 2016-07-12 Eaglepharma Pty Ltd Composition for the treatment of inflammatory and immune disorders
GB2544630A (en) * 2015-11-19 2017-05-24 The Wwk Trust Combinations for the treatment of dementia, and the enhancement of cognitive function
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
JP2022529781A (ja) 2019-04-17 2022-06-24 コンパス パスファインダー リミテッド サイロシビンによるうつ病及び他の様々な障害の治療
CN110237062A (zh) * 2019-07-10 2019-09-17 吉林农业大学 一种以葡萄糖胺为调节剂的能够增强注意力的制剂
US12240813B2 (en) 2020-05-19 2025-03-04 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
KR20230024378A (ko) * 2020-06-12 2023-02-20 벡클리 싸이테크 리미티드 5-메톡시-n, n-디메틸트립타민의 벤조에이트 염을 포함하는 조성물
AU2023378253A1 (en) * 2022-11-07 2025-04-24 Société des Produits Nestlé S.A. Compositions and methods using glycine to reduce biological age of an adult animal

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1882602A (zh) * 2003-10-10 2006-12-20 梅迪泰克研究有限公司 在疾病治疗中乙酰透明质酸合成的调节和降解
CN101317684A (zh) * 2007-06-08 2008-12-10 张文彪 一种固体饮料及制作方法
US20090110674A1 (en) * 2007-10-24 2009-04-30 Loizou Nicos C Health supplement

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4616039A (en) * 1979-08-30 1986-10-07 Herschler R J Methylsulfonylmethane in dietary products
US20040005304A1 (en) * 2002-07-08 2004-01-08 Mak Wood, Inc. Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions
US20060281822A1 (en) * 2005-04-20 2006-12-14 Cardinal Associates, Inc. Treatment and prevention of elevated homocysteine
US20100168053A1 (en) * 2008-03-17 2010-07-01 Revitapop Oral delivery system for methylcobalamin to treat disorders
CA2793612C (fr) * 2010-03-31 2019-06-25 Abela Pharmaceuticals, Inc. Formulations de dimethylsulfoxyde (dmso) pour traiter l'autisme

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1882602A (zh) * 2003-10-10 2006-12-20 梅迪泰克研究有限公司 在疾病治疗中乙酰透明质酸合成的调节和降解
CN101317684A (zh) * 2007-06-08 2008-12-10 张文彪 一种固体饮料及制作方法
US20090110674A1 (en) * 2007-10-24 2009-04-30 Loizou Nicos C Health supplement

Also Published As

Publication number Publication date
EP2624821A1 (fr) 2013-08-14
CA2816595C (fr) 2018-11-27
EP2624821A4 (fr) 2014-02-26
WO2012045118A9 (fr) 2017-04-13
US20130281401A1 (en) 2013-10-24
WO2012045118A1 (fr) 2012-04-12
CN103249407A (zh) 2013-08-14
AU2011313814B2 (en) 2015-12-24
AU2011313814A1 (en) 2013-05-02
CA2816595A1 (fr) 2012-04-12
US20170304351A1 (en) 2017-10-26
EP2624821B1 (fr) 2018-06-27

Similar Documents

Publication Publication Date Title
CN103249407A (zh) 用于治疗抑郁症和其他非感染性疾病的联合疗法
Protic et al. New targeted treatments for fragile X syndrome
TWI776407B (zh) 激動劑形成之調配物及使用其之方法
US20230210930A1 (en) Compositions and methods for treating depression
US20170042878A1 (en) Compositions comprising scopolamine and ketamine in the treatment of depression
JP2007513956A (ja) 鎮静剤と神経伝達物質調節剤の併用、および睡眠の質の向上方法および鬱の治療方法
AU2018343256A1 (en) Treatment of Fragile X Syndrome with cannabidiol
JP2024050575A (ja) Ｌ－４－クロロキヌレニンの治療的使用
CN103906520A (zh) 用于治疗行为和精神病症的鲨肌醇
JP2022514510A (ja) うつ病の治療方法
JP2005512965A (ja) 不穏四肢症候群および定期的四肢運動障害の処置に有用な抗痙攣誘導体
CN107835695A (zh) 用于治疗自闭症的组合物和方法
JP2009500420A (ja) エスゾピクロン及びｏ−デスメチルベンラファキシンの組み合わせ、並びに閉経期並びに気分、不安、及び認知障害の治療方法
JP7681328B2 (ja) 自閉症スペクトル障害の治療における使用のためのバフィデムスタット
AU2017397463A1 (en) Compositions and methods for treating depression
CA3042699C (fr) Compositions et methodes de traitement de la depression
JP2025121388A (ja) 認知機能を改善するための薬物を調製するための組成物の使用
Sacak et al. P. 4. e. 010 The comorbidity of metabolic syndrome in patients with obsessive compulsive disorder
Sequeira Central nervous system stimulants and drugs that suppress appetite
AU2023383549A1 (en) Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use
Mahmood et al. EFFECTS OF L-CARNITINE ON SERUM LEPTIN AND LIPID PROFILE IN ALLOXAN-INDUCED DIABETIC RABBIT
JP2007511577A (ja) （２ｓ，３ｓ）−２−（３−クロロフェニル）−３，５，５−トリメチル−２−モルホリノールの使用
HK1257800B (en) Therapeutic uses of l-4-chlorokynurenine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant